CoChat
Sign Up
Cited by 316Cancer survivorship and careMental Health Treatment and AccessAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline

Open access
Grassi, L., Caruso, R., Riba, M.B., Lloyd-Williams, M., Kissane, D., Rodin, G., McFarland, D., Campos-Ródenas, R., Zachariae, R., Santini, D., Ripamonti, C.I.·2023·ESMO Open
DOI 10.1016/j.esmoop.2023.101155PMC PMC10163167
Open this paper in CoChat — free accountOpen PDF

Abstract

•Anxiety and depressive disorders are common in patients with cancer.•A higher prevalence seen in patients with cancer than the general population is often underrecognised.•Psychotherapy, cognitive behavioural therapy and mindfulness-based therapies are effective treatments.•Psychopharmacological treatments have been shown to be effective treatments of anxiety and depressive disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.esmoop.2023.101155

Cites

0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Screening and management of anxiety symptoms/disorders. Purple: general categories or stratification; white: other aspects of management; turquoise: systemic therapy. AD, antidepressant; CBT, cognitive behavioural therapy; GAD, generalised anxiety disorder; MBT, mindfulness-based therapy; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. aAt diagnosis, treatment, conclusion of treatment, recurrence and when relevant. bAnxious mood (feeling tense, worried), rumination about recurrence is disabling, sleep disturbance, agitation, difficulty in concentration. cAs appropriate.
Figure 1 Screening and management of anxiety symptoms/disorders. Purple: general categories or stratification; white: other aspects of management; turquoise: systemic therapy. AD, antidepressant; CBT, cognitive behavioural therapy; GAD, generalised anxiety disorder; MBT, mindfulness-based therapy; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. aAt diagnosis, treatment, conclusion of treatment, recurrence and when relevant. bAnxious mood (feeling tense, worried), rumination about recurrence is disabling, sleep disturbance, agitation, difficulty in concentration. cAs appropriate.CC BY-NC-ND · PubMed Central
Figure 2 Screening and management of depressive symptoms. Purple: general categories or stratification; white: other aspects of management; turquoise: systemic therapy. ACT, acceptance and commitment therapy; AD, antidepressant; BDI-II, Beck Depression Inventory, second edition; CALM, Managing Cancer and Living Meaningfully; CBSR, cognitive behavioural stress reduction; CBT, cognitive behavioural therapy; MBT, mindfulness-based therapy; PHQ-9, Patient Health Questionnaire-9; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. aAt diagnosis, treatment, conclusion of treatment, recurrence and when relevant. bDepressed mood (feeling down, depressed, helpless/hopeless); anhedonia (little interest or pleasure in doing things). cAs appropriate.
Figure 2 Screening and management of depressive symptoms. Purple: general categories or stratification; white: other aspects of management; turquoise: systemic therapy. ACT, acceptance and commitment therapy; AD, antidepressant; BDI-II, Beck Depression Inventory, second edition; CALM, Managing Cancer and Living Meaningfully; CBSR, cognitive behavioural stress reduction; CBT, cognitive behavioural therapy; MBT, mindfulness-based therapy; PHQ-9, Patient Health Questionnaire-9; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. aAt diagnosis, treatment, conclusion of treatment, recurrence and when relevant. bDepressed mood (feeling down, depressed, helpless/hopeless); anhedonia (little interest or pleasure in doing things). cAs appropriate.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 79

  1. Wang, 2020, Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies, Mol Psychiatry, 25, 1487, 10.1038/s41380-019-0595-x · DOI · Paper page
  2. Caruso, 2017, Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review, Acta Oncol, 56, 146, 10.1080/0284186X.2016.1266090 · DOI · Paper page
  3. Herrman, 2019, Reducing the global burden of depression: a Lancet-World Psychiatric Association Commission, Lancet, 393, e42, 10.1016/S0140-6736(18)32408-5 · DOI
  4. Friedrich, 2017, Depression is the leading cause of disability around the world, JAMA, 317, 1517
  5. Grassi, 2018, Screening for emotional disorders in patients with cancer using the Brief Symptom Inventory (BSI) and the BSI-18 versus a standardized psychiatric interview (the World Health Organization Composite International Diagnostic Interview), Cancer, 124, 2415, 10.1002/cncr.31340 · DOI
  6. Passik, 1998, Oncologists’ recognition of depression in their patients with cancer, J Clin Oncol, 16, 1594, 10.1200/JCO.1998.16.4.1594 · DOI
  7. Keller, 2004, Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach, Ann Oncol, 15, 1243, 10.1093/annonc/mdh318 · DOI
  8. Kissane, 2014, Unrecognised and untreated depression in cancer care, Lancet Psychiatry, 1, 320, 10.1016/S2215-0366(14)70345-1 · DOI
  9. Grassi, 2020, Cancer and severe mental illness: bi-directional problems and potential solutions, Psychooncology, 29, 1445, 10.1002/pon.5534 · DOI
  10. Walker, 2014, Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data, Lancet Psychiatry, 1, 343, 10.1016/S2215-0366(14)70313-X · DOI · Paper page
  11. Zabora, 2001, The prevalence of psychological distress by cancer site, Psychooncology, 10, 19, 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6 · DOI · Paper page
  12. Linden, 2012, Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age, J Affect Disord, 141, 343, 10.1016/j.jad.2012.03.025 · DOI · Paper page
  13. Lebel, 2016, From normal response to clinical problem: definition and clinical features of fear of cancer recurrence, Support Care Cancer, 24, 3265
  14. Soleimani, 2020, Death anxiety in patients with cancer: a systematic review and meta-analysis, Eur J Oncol Nurs, 48, 10.1016/j.ejon.2020.101803 · DOI
  15. Grossman, 2018, Death anxiety interventions in patients with advanced cancer: a systematic review, Palliat Med, 32, 172, 10.1177/0269216317722123 · DOI · Paper page
  16. Hartung, 2017, The risk of being depressed is significantly higher in cancer patients than in the general population: prevalence and severity of depressive symptoms across major cancer types, Eur J Cancer, 72, 46, 10.1016/j.ejca.2016.11.017 · DOI · Paper page
  17. Grassi, 2016, Demoralization syndrome: new insights in psychosocial cancer care, Cancer, 122, 2130, 10.1002/cncr.30022 · DOI
  18. Tecuta, 2015, Demoralization: a systematic review on its clinical characterization, Psychol Med, 45, 673, 10.1017/S0033291714001597 · DOI
  19. Tang, 2015, A systematic review and meta-analysis of demoralization and depression in patients with cancer, Psychosomatics, 56, 634, 10.1016/j.psym.2015.06.005 · DOI
  20. Arrieta, 2013, Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer, Ann Surg Oncol, 20, 1941, 10.1245/s10434-012-2793-5 · DOI
  21. Lebel, 2017, Current state and future prospects of research on fear of cancer recurrence, Psychooncology, 26, 424, 10.1002/pon.4103 · DOI
  22. Yang, 2017, The relationship between cancer patient’s fear of recurrence and chemotherapy: a systematic review and meta-analysis, J Psychosom Res, 98, 55, 10.1016/j.jpsychores.2017.05.002 · DOI
  23. Yang, 2017, The relationship between cancer patient’s fear of recurrence and radiotherapy: a systematic review and meta-analysis, Psychooncology, 26, 738, 10.1002/pon.4224 · DOI
  24. Walker, 2013, Prevalence of depression in adults with cancer: a systematic review, Ann Oncol, 24, 895, 10.1093/annonc/mds575 · DOI
  25. Ahmad, 2021, Pathophysiological implications of neuroinflammation mediated HPA axis dysregulation in the prognosis of cancer and depression, Mol Cell Endocrinol, 520, 10.1016/j.mce.2020.111093 · DOI
  26. McFarland, 2021, Clinical implications of cancer related inflammation and depression: a critical review, Clin Pract Epidemiol Ment Health, 17, 287, 10.2174/1745017902117010287 · DOI
  27. Rebello, 2019, Anxiety and fear-related disorders in the ICD-11: results from a global case-controlled field study, Arch Med Res, 50, 490, 10.1016/j.arcmed.2019.12.012 · DOI
  28. Belvederi Murri, 2020, The relationship between demoralization and depressive symptoms among patients from the general hospital: network and exploratory graph analysis, J Affect Disord, 276, 137, 10.1016/j.jad.2020.06.074 · DOI
  29. Bruera, 1991, The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients, J Palliat Care, 7, 6, 10.1177/082585979100700202 · DOI
  30. Mitchell, 2010, Short screening tools for cancer-related distress: a review and diagnostic validity meta-analysis, J Natl Compr Canc Netw, 8, 487, 10.6004/jnccn.2010.0035 · DOI
  31. Mattsson, 2019, Identification of anxiety and depression symptoms in patients with cancer: comparison between short and long web-based questionnaires, J Med Internet Res, 21, 10.2196/11387 · DOI
  32. Andersen, 2014, Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation, J Clin Oncol, 32, 1605, 10.1200/JCO.2013.52.4611 · DOI · Paper page
  33. Butow, 2015, Clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients: Australian guidelines, Psychooncology, 24, 987, 10.1002/pon.3920 · DOI
  34. Vodermaier, 2011, Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis, Support Care Cancer, 19, 1899
  35. Ripamonti, 2014, The Edmonton Symptom Assessment System (ESAS) as a screening tool for depression and anxiety in non-advanced patients with solid or haematological malignancies on cure or follow-up, Support Care Cancer, 22, 783
  36. Thewes, 2015, The Concerns About Recurrence Questionnaire: validation of a brief measure of fear of cancer recurrence amongst Danish and Australian breast cancer survivors, J Cancer Surviv, 9, 68, 10.1007/s11764-014-0383-1 · DOI
  37. Hinz, 2015, Fear of progression in patients 6 months after cancer rehabilitation-a- validation study of the fear of progression questionnaire FoP-Q-12, Support Care Cancer, 23, 1579
  38. Lloyd-Williams, 2021, Socio-economic deprivation and symptom burden in UK hospice patients with advanced cancer-findings from a longitudinal study, Cancers (Basel), 13, 2537, 10.3390/cancers13112537 · DOI
  39. Ripamonti, 2020, The validation of the Italian version of the COmprehensive Score for financial Toxicity (COST), Support Care Cancer, 28, 4477
  40. Ryan, 2012, Sensitivity and specificity of the Distress Thermometer and a two-item depression screen (Patient Health Questionnaire-2) with a ‘help’ question for psychological distress and psychiatric morbidity in patients with advanced cancer, Psychooncology, 21, 1275, 10.1002/pon.2042 · DOI · Paper page
  41. Warmenhoven, 2012, The Beck Depression Inventory (BDI-II) and a single screening question as screening tools for depressive disorder in Dutch advanced cancer patients, Support Care Cancer, 20, 319
  42. Christensen, 2009, Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer, Breast Cancer Res Treat, 113, 339, 10.1007/s10549-008-9920-9 · DOI
  43. Mitchell, 2012, Meta-analysis of screening and case finding tools for depression in cancer: evidence based recommendations for clinical practice on behalf of the Depression in Cancer Care consensus group, J Affect Disord, 140, 149, 10.1016/j.jad.2011.12.043 · DOI · Paper page
  44. Rayner, 2009, The detection of depression in palliative care, Curr Opin Support Palliat Care, 3, 55, 10.1097/SPC.0b013e328326b59b · DOI
  45. Thekkumpurath, 2011, Screening for major depression in cancer outpatients: the diagnostic accuracy of the 9-item patient health questionnaire, Cancer, 117, 218, 10.1002/cncr.25514 · DOI
  46. Lloyd-Williams, 2007, The development of the Brief Edinburgh Depression Scale (BEDS) to screen for depression in patients with advanced cancer, J Affect Disord, 99, 259, 10.1016/j.jad.2006.09.015 · DOI
  47. Rodriguez-Mayoral, 2021, Comparing the hospital anxiety and depression scale to the Brief Edinburgh Depression Scale for identifying cases of major depressive disorder in advanced cancer palliative patients, Palliat Support Care, 19, 170, 10.1017/S1478951520000760 · DOI
  48. Hartung, 2017, The Hospital Anxiety and Depression Scale (HADS) and the 9-item Patient Health Questionnaire (PHQ-9) as screening instruments for depression in patients with cancer, Cancer, 123, 4236, 10.1002/cncr.30846 · DOI
  49. Rankin, 2015, Everybody wants it done but nobody wants to do it: an exploration of the barrier and enablers of critical components towards creating a clinical pathway for anxiety and depression in cancer, BMC Health Serv Res, 15, 28, 10.1186/s12913-015-0691-9 · DOI
  50. Caruso, 2017, Depressive spectrum disorders in cancer: diagnostic issues and intervention. A critical review, Curr Psychiatry Rep, 19, 33, 10.1007/s11920-017-0785-7 · DOI
  51. Trevino, 2014, Patient-oncologist alliance as protection against suicidal ideation in young adults with advanced cancer, Cancer, 120, 2272, 10.1002/cncr.28740 · DOI
  52. Trevino, 2013, Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer, J Clin Oncol, 31, 1683, 10.1200/JCO.2012.46.7993 · DOI
  53. Caruso, 2013, Psychopharmacology in psycho-oncology, Curr Psychiatry Rep, 15, 393, 10.1007/s11920-013-0393-0 · DOI
  54. Fitzgerald, 2015, The relationship between depression and physical symptom burden in advanced cancer, BMJ Support Palliat Care, 5, 381, 10.1136/bmjspcare-2012-000380 · DOI · Paper page
  55. 2017, Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment, Ont Health Technol Assess Ser, 17, 1
  56. Martinez, 2017, ‘Dignity therapy’, a promising intervention in palliative care: a comprehensive systematic literature review, Palliat Med, 31, 492, 10.1177/0269216316665562 · DOI · Paper page
  57. Breitbart, 2018, Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: a randomized controlled trial in patients with advanced cancer, Cancer, 124, 3231, 10.1002/cncr.31539 · DOI · Paper page
  58. Grassi, 2014, Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review, Int Rev Psychiatry, 26, 44, 10.3109/09540261.2013.842542 · DOI
  59. Heron-Speirs, 2013, Moderators of psycho-oncology therapy effectiveness: meta-analysis of therapy characteristics, J Psychosoc Oncol, 31, 617, 10.1080/07347332.2013.835022 · DOI
  60. Tauber, 2019, Effect of psychological intervention on fear of cancer recurrence: a systematic review and meta-analysis, J Clin Oncol, 37, 2899, 10.1200/JCO.19.00572 · DOI · Paper page
  61. Salt, 2017, Drug therapy for symptoms associated with anxiety in adult palliative care patients, Cochrane Database Syst Rev, 5, CD004596
  62. Panjwani, 2021, Recent trends in the management of depression in persons with cancer, Curr Opin Psychiatry, 34, 448, 10.1097/YCO.0000000000000727 · DOI
  63. Thom, 2019, Major depressive disorder in medical illness: a review of assessment, prevalence, and treatment options, Psychosom Med, 81, 246, 10.1097/PSY.0000000000000678 · DOI
  64. Ng, 2014, Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study, Eur Neuropsychopharmacol, 24, 491, 10.1016/j.euroneuro.2014.01.016 · DOI · Paper page
  65. Grassi, 2018, The use of antidepressants in oncology: a review and practical tips for oncologists, Ann Oncol, 29, 101, 10.1093/annonc/mdx526 · DOI
  66. Bradbury, 2022, Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review, Clin Breast Cancer, 22, e362, 10.1016/j.clbc.2021.10.003 · DOI
  67. Johnson, 2018, A research study review of effectiveness of treatments for psychiatric conditions common to end-stage cancer patients: needs assessment for future research and an impassioned plea, BMC Psychiatry, 18, 85, 10.1186/s12888-018-1651-9 · DOI
  68. Ostuzzi, 2015, Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: systematic review and meta-analysis, Cancer Treat Rev, 41, 714, 10.1016/j.ctrv.2015.06.003 · DOI
  69. Ziegler, 2011, Identifying psychological distress at key stages of the cancer illness trajectory: a systematic review of validated self-report measures, J Pain Symptom Manage, 41, 619, 10.1016/j.jpainsymman.2010.06.024 · DOI
  70. Bravery, 2020, Depression treatment research in people with cancer does not reflect cancer prevalence: findings from a systematic review, Evid Based Ment Health, 23, 155, 10.1136/ebmental-2020-300145 · DOI
  71. Donovan, 2020, Advancing the science of distress screening and management in cancer care, Epidemiol Psychiatr Sci, 29, e85, 10.1017/S2045796019000799 · DOI · Paper page
  72. Clover, 2015, Why do oncology outpatients who report emotional distress decline help?, Psychooncology, 24, 812, 10.1002/pon.3729 · DOI · Paper page
  73. Tondorf, 2018, Focusing on cancer patients’ intentions to use psychooncological support: a longitudinal, mixed-methods study, Psychooncology, 27, 1656, 10.1002/pon.4735 · DOI
  74. Meggiolaro, 2021, From distress screening to uptake: an Italian multicenter study of cancer patients, Cancers (Basel), 13, 3761, 10.3390/cancers13153761 · DOI
  75. Partridge, 2015, Challenges to standardizing the care for adult cancer survivors: highlighting ASCO’s fatigue and anxiety and depression guidelines, Am Soc Clin Oncol Educ Book, 35, 188, 10.14694/EdBook_AM.2015.35.188 · DOI
  76. Frey Nascimento, 2019, Oncologist recommendation matters!-Predictors of psycho-oncological service uptake in oncology outpatients, Psychooncology, 28, 351, 10.1002/pon.4948 · DOI
  77. McCarter, 2018, Interventions to improve screening and appropriate referral of patients with cancer for psychosocial distress: systematic review, BMJ Open, 8, 10.1136/bmjopen-2017-017959 · DOI
  78. Zebrack, 2015, Psychosocial distress screening implementation in cancer care: an analysis of adherence, responsiveness, and acceptability, J Clin Oncol, 33, 1165, 10.1200/JCO.2014.57.4020 · DOI
  79. Dykewicz, 2001, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, Clin Infect Dis, 33, 139, 10.1086/321805 · DOI

Cited by

Sorted by citations

Items 101–200 of 283

Metadata

Authors
Grassi, L., Caruso, R., Riba, M. B., Lloyd-Williams, M., Kissane, D., Rodin, G., McFarland, D., Campos-Ródenas, R., Zachariae, R., Santini, D., & Ripamonti, C. I.
Affiliations
  • University of Ferrara (IT)
  • University of Michigan (US)
  • Monash Medical Centre (AU)
  • Princess Margaret Cancer Centre (CA)
  • University of Rochester Medicine (US)
  • Aarhus University (DK)
  • Sapienza University of Rome (IT)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
ORCID
Venue
ESMO Open
Publisher
Elsevier BV
Published
2023-04
Volume
8
Issue
2
Pages
101155
ISSN
2059-7029 (ISSN-L)
DOI
10.1016/j.esmoop.2023.101155
PMC
PMC10163167
OpenAlex
W4324143593
Cited by
316
References
125
Citations by year
2026: 128 · 2025: 106 · 2024: 76 · 2023: 6
FWCI
38.54
Type
journal article
Language
en
Open access
Licence
Locations
  • ESMO Open (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by-nc-nd)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
  • Liverpool John Moores University (submittedVersion)
  • Zaguan (Universidad de Zaragoza) (submittedVersion, cc-by-nc-nd)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
Funders
European Society for Medical Oncology
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
anxiety, depression, cancer patients, psycho-oncology, cognitive behavioral therapy, mindfulness-based interventions, psychopharmacological treatment, prevalence of mental disorders
MeSH terms
Adult, Anxiety, Depression, Humans, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review